The $19 Billion Reset: How CMS Just Blew Up Skin Substitute Reimbursement — and What It Means for Every Wound Care Provider

There are policy changes that tweak the margins, and there are policy changes that restructure an entire industry. What CMS did to skin substitute reimbursement on January 1, 2026, belongs in the second category. In a single rulemaking cycle, the agency effectively dismantled a payment model that had allowed Medicare Part B spending on wound care products to explode from $256 million in 2019 to over $10 billion in 2024 — a 40-fold increase. CMS projects its new approach will reduce gross fee-for-service spending on skin substitute services by $19.6 billion in 2026 alone — nearly a 90% reduction — while, in the agency’s words, “incentivizing the use of products with the most clinical evidence of success.”

Whether that projection proves accurate, and whether the savings come at the cost of legitimate patient access, is the central question now facing wound care specialists, dermatologists, podiatrists, and the manufacturers who have built an industry around this market. The honest answer is: no one knows yet. But what is certain is that the old model is gone, and practices that haven’t yet adapted are operating on borrowed time.

How It Worked — and Why It Broke

To understand the magnitude of the change, you need to understand the system it replaced. Until 2025, most skin substitutes were paid as biologicals under the average sales price (ASP)-based payment methodology described in Section 1847A of the Social Security Act. Under that system, manufacturers set their own prices, reported ASP data to CMS, and were reimbursed at ASP plus 6%. In practice, prices could reach as high as $2,000 per square inch.

The perverse incentives built into ASP+6% are not subtle. When a physician earns a percentage markup on the price of a product, they have a direct financial interest in selecting the most expensive version of that product, regardless of clinical differentiation. Part B spending exploded from $252 million in 2019 to over $10 billion in 2024 — a nearly 40-fold increase — while patient volume only roughly doubled. The gap between volume growth and spending growth is almost entirely explained by price inflation, not utilization of care.

The OIG investigated and found systematic manipulation of the payment system. An OIG report found that Medicare spending on skin substitutes had increased by more than 640% over two years and accounted for over 15% of all Part B drug expenditures. Investigators documented patterns including multiple claims submitted on the same date to stay below automated payment-denial thresholds, billing by clinicians in specialties entirely unrelated to wound care, and the use of skin substitutes without any prior conservative treatment. In one high-profile case investigated jointly by the OIG, the FBI, and other federal agencies, a couple in Arizona pleaded guilty to orchestrating a $1.2 billion fraud scheme involving medically unnecessary wound grafts.

In 2025 alone, the CMS Fraud Defense Operations Center stopped nearly $185 million in improper payments to suspect providers billing for skin substitutes. In one case identified in September 2025, the center stopped more than $4.3 million in suspected improper payments submitted by a medical group practice — virtually all of it for wound care services purportedly provided to a single beneficiary who lacked evidence of prior wound treatment.

By 2025, the political and fiscal pressure to act was overwhelming, cutting across both parties. The question was not whether to reform the system — it was how aggressively.

The New Architecture: What Actually Changed

Effective January 1, 2026, CMS classifies most skin substitute products as “incident-to” supplies when they are used as part of a covered application procedure — whether paid under the Medicare Physician Fee Schedule in a non-facility setting, or under the OPPS in a hospital outpatient department. This is a categorical shift with major financial consequences.

In the old world, the product itself was a billable item — a drug-like product paid separately at a price point that manufacturers largely controlled. In the new world, Medicare pays a flat rate of $127.14 per square centimeter. The ASP-based payment methodology is eliminated for most products. Application services remain separately reimbursable, for now.

CMS finalized three payment groups based on FDA regulatory classification: products governed under Section 361 of the Public Health Service Act (a subset of Human Cells, Tissues, and Cellular and Tissue-Based Products, or HCT/Ps); devices requiring 510(k) clearance; and products subject to Premarket Approval (PMA) applications. For 2026, all three categories receive the same flat rate of $127.14 per square centimeter regardless of which regulatory pathway a product used to reach the market. CMS has indicated that separate, differentiated rates for the three categories are expected by 2027 — the single rate for 2026 was a deliberate choice to allow the market to stabilize under the new system before introducing further complexity.

One important carve-out: only skin substitute products covered by a biologics license under Section 351 of the Public Health Service Act will continue to be paid under the ASP methodology. Section 351 products are relatively rare in the wound care space due to the substantial regulatory burden — they must undergo full clinical trials demonstrating safety and efficacy and comply with rigorous manufacturing controls. Most skin substitute manufacturers have chosen less rigorous regulatory pathways that allow faster market entry with lower development costs.

It is also critical to note what did not take effect. CMS had been preparing to implement final Local Coverage Determinations (LCDs) for skin substitutes used in diabetic foot ulcers and venous leg ulcers, which would have imposed stricter coverage standards including requirements related to duration of standard care, documentation of clinical progress, vascular assessment, and evidentiary support. In late December 2025, just days before they were set to take effect, those LCDs were withdrawn. The payment reform moved forward; the coverage tightening did not — at least not yet. The result is a hybrid state: dramatically lower rates are in force, but coverage criteria remain largely as they were.

Who Gets Hurt — and How Much

The financial impact is not evenly distributed. It falls hardest on physician offices and mobile wound care providers, which represent the vast majority of skin substitute utilization and the settings where ASP+6% incentives were most aggressively exploited.

Because their patient population skews heavily toward Medicare beneficiaries, mobile wound care providers depend on Medicare reimbursement as their core revenue stream. Uniform payment reductions threaten their financial viability, discouraging acquisition and application of advanced wound care supplies. The concern is not abstract. For many physician practices, skin substitute applications had become an important revenue stream. With flat-fee reimbursement replacing ASP plus 6%, the financial viability of in-office wound care programs will be affected — and many physicians may decide it is not financially sustainable to continue providing this service, raising access concerns particularly in rural areas where the number of available providers may decline significantly.

The equity dimension compounds this problem. Reduced reimbursement for advanced wound care risks limiting access for the very populations most vulnerable to chronic wounds and their complications. Patients with diabetic foot ulcers and venous leg ulcers — disproportionately elderly, low-income, and living in areas with limited specialist access — are precisely the population that relied on the now-squeezed mobile wound care infrastructure.

Office-based and mobile wound care providers will see significant reimbursement cuts, while hospital outpatient departments are likely to gain referral volume as clinics reevaluate financial viability. This site-of-care shift carries its own implications: hospital outpatient services are generally more expensive for patients in terms of cost-sharing, and less accessible for patients without reliable transportation.

For manufacturers, the damage is structural. The old model was profitable precisely because reimbursement was tied to price — companies could charge more and generate both higher revenues and higher reimbursements. Without differentiated payment, manufacturers may reduce investment in new therapies, halting an area of innovation that has grown substantially in recent years. With potentially lower revenue levels, money spent on product innovation may shift to areas of higher profit.

The Enforcement Environment: Not Just a Payment Change

The 2026 rule is not arriving in a vacuum. CMS’s 2026 reimbursement overhaul signals more than cost control — it marks a sharp rise in audits, enforcement, and compliance risk for wound care providers. The fraud history that justified the payment change has also put every legitimate provider in a heightened scrutiny environment.

Contractors such as Unified Program Integrity Contractors, Recovery Audit Contractors, and Medicare Administrative Contractors typically target outlier practices with unusually high usage of high-cost skin substitutes. When auditors are actively looking for fraud, waste, and abuse, they tend to find something to grab onto. Documentation lapses — insufficient wound measurements, missing prior care data, or use of skin substitutes without adequate conservative care — can lead to seven-figure overpayment demands.

Some distributors may suggest that nothing has changed due to the LCD withdrawal. Providers and wound care clinics should not accept this framing. The payment changes are fully in effect. With payment changes in force but coverage rules unchanged, providers must carefully review their billing and compliance protocols to avoid errors or denials.

Divided Stakeholders, Unresolved Questions

Reaction to the rule has split along predictable but illuminating lines. The Alliance of Wound Care Stakeholders expressed support for the change, praising CMS for its “efforts to combat fraud, waste and abuse of these products and address the excessive spending that has made the current payment methodology unsustainable.” By contrast, Medicare Access to Skin Substitutes — which represents manufacturers, processors, and distributors — argues that the changes will put “patients at risk of infection, amputation, and death.”

Both positions contain truth. The scale of documented fraud and abuse in this market is staggering and demanded a response. The previous system had become a vehicle for billing manipulation that had little to do with patient care. At the same time, legitimate providers serving genuinely complex wound patients do exist, and the flat rate of $127 per square centimeter does not reflect the clinical or economic reality of the most advanced products.

The agency’s theory — that market competition under a single price point will drive innovation and lower costs — is economically coherent but has not been tested at this scale in wound care. Whether it produces a healthier market or simply collapses a segment of legitimate care delivery is a question that 2026 claims data will begin to answer.

What Providers Must Do Now

First: audit your product inventory and cost structure. High-cost products purchased in 2025 are likely to face reduced reimbursement levels in 2026, potentially creating funding gaps. Providers should reassess procurement and billing strategies immediately.

Second: treat documentation as a compliance asset, not a formality. CMS emphasized documentation as a core safeguard against overutilization and non-compliance. Providers will need to demonstrate medical necessity and appropriateness for every application — accurate, consistent, and reproducible documentation is no longer just good clinical practice, it’s financial defense.

Third: monitor the LCD situation closely. The withdrawn LCDs may be re-proposed. CMS indicated it will continue to monitor utilization, claims patterns, and clinical outcomes following implementation. A second round of coverage tightening, now informed by 2026 utilization data, is plausible within the next rulemaking cycle.

Fourth: model the 2027 rate differentiation. The current single flat rate for all three FDA regulatory categories will likely give way to differentiated rates in 2027. Products that have undergone the more rigorous PMA review pathway may receive higher reimbursement. Practices should begin mapping their product mix against FDA regulatory categories now.

Fifth: assume your utilization data is being reviewed. If your clinic derives substantial revenue from skin substitute billing, diabetic foot ulcer treatment, or venous leg ulcer advanced wound care services, you are operating in a heightened enforcement environment. Silence from regulators does not mean safety — it often means data analysis is underway.

The Bigger Picture

What CMS has done with skin substitutes is not purely about wound care. It is a template. The agency identified a product category where the payment methodology had become systematically distorted by financial incentives disconnected from clinical value, documented the fraud and overutilization that resulted, and replaced an ad valorem system with a flat rate designed to neutralize those incentives. The $19.6 billion projected savings in a single year represents one of the largest payment policy corrections in Medicare’s history.

The lesson for every specialty that relies on product-based reimbursement is clear: if spending in your category is growing 40-fold in five years, CMS will eventually look at why. And when it does, the response will not be incremental.

Sources

1. CMS Press Release: “CMS Modernizes Payment Accuracy and Significantly Cuts Spending Waste,” October 31, 2025 — cms.gov
2. CMS Fact Sheet: “Calendar Year 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)” — cms.gov
3. Applied Policy: “Skin Substitutes in Medicare: Trends, Challenges, and CMS’s Policy Response,” December 2025 — appliedpolicy.com
4. BDO Advisory: “CMS Withdraws Prominent LCD for Skin Substitutes: What Healthcare Providers Need to Know,” January 2026 — bdo.com
5. Hendershot Cowart P.C.: “CMS Reclassifies Skin Substitutes for 2026: Key Changes,” December 2025 — hchlawyers.com
6. Reed Smith, Health Industry Washington Watch: “CMS Reclassifies Certain Skin Substitutes and Dramatically Cuts Payment Under Medicare Part B,” November 2025 — reedsmith.com
7. Sidley Austin LLP: “Medicare Payment Policy Final Rule for Outpatient Setting Addresses Skin Substitutes,” December 2025 — sidley.com
8. American Bar Association Health Law: “Skin Substitute Crackdown Is Wounding Providers and Patients,” March 2026 — americanbar.org
9. Medical Economics: “The 2026 Medicare Physician Fee Schedule Marks a Watershed Moment for Wound Care and Skin Substitutes,” December 2025 — medicaleconomics.com
10. Swift Medical: “2026 CMS Skin Substitute Rule: Understanding the Clinical and Financial Impact” — swiftmedical.com
11. Health Law Alliance: “CMS Skin Substitute Reimbursement Limitations Signal Continued Scrutiny of Wound Care Providers in 2026,” March 2026 — healthlawalliance.com